-+ 0.00%
-+ 0.00%
-+ 0.00%

Tiziana Life Sciences signs MOU at Riyadh Global Medical Biotechnology Summit

PUBT·09/17/2026 11:05:19
Listen to the news
Tiziana Life Sciences signs MOU at Riyadh Global Medical Biotechnology Summit
  • Tiziana signed an MOU at the Riyadh Global Medical Biotechnology Summit in Riyadh on September 16, 2026.
  • Agreement targets a clinical trial combining intranasal foralumab with anti-CD20 therapy in relapsing-remitting multiple sclerosis.
  • Trial would focus on patients responding poorly to anti-CD20 therapy alone, potentially due to untreated neuroinflammation.
  • Partners include King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, and the Foundation for Neurologic Diseases.
  • MOU adds a relapsing-remitting MS program while the company keeps its blinded Phase 2 trial in non-active secondary progressive MS.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief on September 17, 2026, and is solely responsible for the information contained therein.